ArticleCurrent hepatitis reports2011
Management of Hepatitis C Antiviral Therapy Adverse Effects.
Article in Current hepatitis reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection.Scientific reports · 2022Article
- Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar.World journal of gastroenterology · 2021Article
- Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.Viruses · 2020Review
- Current and Promising Antivirals Against Chikungunya Virus.Frontiers in public health · 2020Review
- Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder.Current pharmaceutical design · 2020Review
- Comparing drug safety of hepatitis C therapies using post-market data.BMC medical informatics and decision making · 2019Article
- The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.Journal of clinical and translational hepatology · 2017Review
- Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.The Indian journal of medical research · 2016Article
- Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.Memorias do Instituto Oswaldo Cruz · 2015Article
- Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey.Balkan medical journal · 2015Article
- Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies.Journal of clinical and translational hepatology · 2015Review
- New treatments for chronic hepatitis C: an overview for paediatricians.World journal of gastroenterology · 2014Review
- "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.BMC infectious diseases · 2014Article
- A new era in the treatment of chronic hepatitis C infection.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2013Review
- Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report.World journal of gastroenterology · 2012Review
- A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.Journal of clinical and experimental hepatology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C is one of the leading causes of liver disease in the United States, affecting more than 4 million individuals. The current treatment regimen involves pegylated interferon in combination with ribavirin. Although antiviral treatment has been associated with a greater than 50% sustained viral response rate, the adverse effects have proven to be detrimental to quality of life and therapy adherence, and consequently lead to lower sustained viral response rates. This article identifies the most frequently described complications associated with pegylated interferon and ribavirin. The active management of these complications is discussed, including both preventive and empiric treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.